This product is a methylhydroxyglutaryl coenzyme A (HMG-COA) reductase inhibitor, which inhibits the synthesis of endogenous cholesterol and is a blood lipid regulator. Literature data show that it can reduce the cholesterol (TC) content in the serum, liver, and aorta of hyperlipidemia rabbits, and reduce the levels of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C).

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

The first generation of oral cephalosporin has good antibacterial effect on most strains of penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pneumoniae, group A hemolytic Streptococcus, etc. It also has certain antibacterial activity against Escherichia coli, Proteus mirabilis, Salmonella, Shigella, Haemophilus influenzae and gonococci. Methicillin-resistant Staphylococcus, Enterococcus, indole-positive Proteus, Enterobacter, Serratia and other Enterobacteriaceae, Pseudomonas aeruginosa and Bacteroides fragilis are resistant to this product.

Levetiracetam is a pyrrolidone derivative whose chemical structure is not related to existing anti-epileptic drugs. Its exact mechanism is still unclear, but it has a protective effect on generalized seizures secondary to focal seizures induced by pilocarpine and kainic acid, and has an inhibitory effect on both the kindling process and the kindling state in the rat kindling model of complex partial seizures.

This product is a long-acting tricyclic antihistamine that can relieve seasonal allergic rhinitis or non-nasal symptoms by selectively antagonizing peripheral H1 receptors.